Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rulonilimab by Shandong New Time Pharmaceutical for Cervical Cancer: Likelihood of Approval
Rulonilimab is under clinical development by Shandong New Time Pharmaceutical and currently in Phase II for Cervical Cancer. According to...
Rulonilimab by Shandong New Time Pharmaceutical for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Rulonilimab is under clinical development by Shandong New Time Pharmaceutical and currently in Phase II for Diffuse Large B-Cell Lymphoma....
Rulonilimab by Shandong New Time Pharmaceutical for Hepatocellular Carcinoma: Likelihood of Approval
Rulonilimab is under clinical development by Shandong New Time Pharmaceutical and currently in Phase III for Hepatocellular Carcinoma. According to...
Rulonilimab by Shandong New Time Pharmaceutical for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Rulonilimab is under clinical development by Shandong New Time Pharmaceutical and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL)....